Gynecologic Cancer Vaccinations
January is Cervical Cancer Awareness Month, and CU Cancer Center member Lindsay Brubaker, MD, wants everyone to be aware of the relationship between cervical cancer and the human papillomavirus (HPV), a sexually-transmitted disease that causes the vast majority of cervical cancers. The current HPV vaccine protects against seven predominant strains of the virus that cause cancer, as well as the two that cause genital warts.
Cancer Center | 
January 22, 2021
Press Coverage Gynecologic Cancer
Peyton taught the world that ovarian cancer doesn’t just strike mothers and grandmothers. “She’s brought so much awareness to the disease through her advocacy,” said CU Cancer Center member Saketh Guntupalli, MD.
CBS4 Denver | January 08, 2021
Research Gynecologic Cancer ovarian cancer
After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response.
Cancer Center | September 15, 2020
Last month the American Cancer Society (ACS) released updated guidelines for cervical cancer screening. The most notable change in guidelines is the changes in the age to begin screening. Per the new guidelines, it is recommended that cervical cancer screening begin at age 25. Previously, the starting age for screening was 21.
Cancer Center | August 18, 2020
Philanthropy Gynecologic Cancer Cancer ovarian cancer
In July 2019, Emily McClintock Addlesperger was on vacation in Maine with her husband, Jason, when she felt sick and was airlifted to Portland with internal bleeding. A tumor on her ovary had burst. It was Monday. On Saturday, she passed away. Emily was 44 years old.
Cancer Center | July 16, 2020
Gynecologic Cancer Clinical Research
Brad Corr’s inspiration to pursue a medical career came on the ski slopes of Big Sky, Montana.
Cancer Center | February 03, 2020
This July, University of Colorado Cancer Center investigator, Saketh Guntupalli, MD, assumes the role of Division Chief of the CU School of Medicine Department of Obstetrics and Gynecology Division of Gynecologic Oncology, with a mission to increase the excellence of clinical care, train the next generation of physician-scientists, and move the needle on gynecologic cancer research. Guntupalli takes over a program that already boasts 15-20 percent improved survival rates over national averages for some cancers including uterine cancer.
Cancer Center | July 01, 2019
Sexual health can be an uncomfortable subject after completing cancer treatment, but is an important quality of life issue. A University of Colorado Cancer Center study presented at the 2019 American Society of Clinical Oncology (ASCO) conference in Chicago highlights the unmet need of interventions to improve and maintain optimal sexual health.
Cancer Center | May 31, 2019
In women at high risk for ovarian cancer, the common prevention strategy is to remove fallopian tubes and ovaries as soon as the woman is done having a family – the sooner the better. But this initiates menopause and along with it higher risk of cardiovascular disease, osteoporosis, sexual side-effects, and perhaps even Alzheimer’s disease. A recent University of Colorado Cancer Center review in the International Journal of Gynecologic Cancer suggests a way young, high-risk women can reduce risk while leaving menopause for later: the technique known as salpingectomy removes the fallopian tubes while leaving ovaries intact.
Garth Sundem | February 20, 2013
5280
January 05, 2022
CU Cancer Center member Neil Box, MD, separates fact from pseudoscience when it comes to protecting yourself from the sun.
Denver 7
December 23, 2021
In 2021, a Crested Butte family received a life-changing diagnosis. During the holiday season, their story is an apparent reminder that sometimes the best gifts are never found under a tree.
Cure Today
December 15, 2021
A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.
Healio
December 11, 2021
Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with relapsed or refractory large B-cell lymphoma, according to study results presented at ASH Annual Meeting and Exposition.
